Kenneth Krogulski - 01 Dec 2022 Form 4 Insider Report for CUMBERLAND PHARMACEUTICALS INC (CPIX)

Role
Director
Signature
Kenneth J. Krogulski by /s/ John Hamm as attorney-in-fact
Issuer symbol
CPIX
Transactions as of
01 Dec 2022
Transactions value $
$6,778
Form type
4
Filing time
23 Dec 2022, 16:07:46 UTC
Previous filing
23 Dec 2022
Next filing
27 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPIX Common Stock Purchase $245 +105 +0.05% $2.33 202,010 01 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $243 +105 +0.05% $2.31 202,115 02 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $230 +105 +0.05% $2.19 202,220 05 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $230 +105 +0.05% $2.19 202,325 06 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $229 +105 +0.05% $2.18 202,430 07 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $230 +105 +0.05% $2.19 202,535 08 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $226 +105 +0.05% $2.15 202,640 09 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $225 +105 +0.05% $2.14 202,745 12 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $698 +320 +0.16% $2.18 203,065 13 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $707 +320 +0.16% $2.21 203,385 14 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $323 +144 +0.07% $2.24 203,529 15 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $546 +246 +0.12% $2.22 203,775 16 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $994 +450 +0.22% $2.21 204,225 19 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $855 +370 +0.18% $2.31 204,595 20 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $799 +360 +0.18% $2.22 204,955 21 Dec 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.